News and Events

News from Wisconsin Alzheimer's Institute

• 

  Updates about federal funding and UW Alzheimer’s disease research

• 

  UW–Madison Alzheimer’s disease researchers present new findings at 2025 international conference

  A team of researchers from the Wisconsin Alzheimer’s Institute joined nearly 19,000 global experts at the 2025 Alzheimer’s Association International Conference (AAIC), held July 27-July 31  in Toronto, Canada. 

• 

  Two leading dementia researchers join UW–Madison

  UW–Madison’s School of Medicine and Public Health is adding Henrik Zetterberg, a Swedish scientist who studies biomarkers, and Hartmuth Kolb, a German-born chemist and expert in imaging technology, to its faculty.

• 

  Bringing memory care strategy and tools to primary care clinics

  Researchers in the public health team at Wisconsin Alzheimer’s Institute are working to understand how to bring research advances and tools from memory clinics into the primary care environment. 

• 

  Dr. Maria Mora Pinzon leads education program to train medical students in advancing dementia care for Latinos

  Researchers in Madison are partnering with a Milwaukee-based Latino community center to create a new, culturally competent, elective course for medical students at the University of Wisconsin School of Medicine and Public Health as an elective.

• 

  Dr. Nathaniel Chin discusses UW–Madison role in Alzheimer’s blood tests on regional media outlets

  Nathaniel Chin, MD, medical director of the WRAP study, appeared on numerous Wisconsin news outlets to discuss the recent Food and Drug Administration (FDA) approval of a blood test for Alzheimer’s disease. The accuracy of the blood test was validated using data samples from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP).

• 

  UW–Madison research helps launch first FDA-cleared blood test for Alzheimer’s disease

  In a crucial advancement for Alzheimer’s disease diagnosis, the U.S. Food and Drug Administration (FDA) granted clearance for an Alzheimer’s disease blood test on May 16, 2025. The test is an in vitro diagnostic (IVD) assay capable of detecting amyloid — a key protein involved in Alzheimer’s disease — in blood. Data samples used to evaluate the validity of the test are from research conducted at the University of Wisconsin–Madison.

• More news from WAI